肿瘤标志物在胰腺良恶性疾病鉴别诊断中临床应用-clinical application of tumor markers in differential diagnosis of benign and malignant pancreatic diseases.docxVIP

上海交通大学医学院硕士学位论文 上海交通大学医学院硕士学位论文 PAGE PAGE 10 CANCER ANTIGENS IN DIFFERENTIAL DIAGNOSIS OF BENIGN AND MALIGNANT PANCREATIC LESIONS ABSTRACT Background and Objectives: Pancreatic cancer is a malignant neoplasm of gastroenterology with very poor prognosis. The mortality of pancreatic cancer is rising up during recent years in our country. The non-specific or even asymptomatic manifestation causes the hardness in making the differential diagnosis of pancreatic cancer and benign pancreatic disease. Establishing a simple, effective, non-invasive and reliable technique which can be used to make the differential diagnosis of pancreatic cancer and benign pancreatic disease have been paid attention by more and more clinical doctors and researchers. Cancer antigens are common used during clinical works, but the ability of making the differential diagnosis of pancreatic cancer and benign pancreatic disease remains controversial. The aim of our research is to compare the serum level of tumor markers CA19-9, CA125 and carcinoembryonic antigen (CEA) in cancer and benign groups and discuss their value in the differential diagnosis of pancreatic cancer and benign pancreatic disease. Methods: Collect 73 cases of pancreatic disease between April 2007 and November 2008 in our hospital. We assay the peripheral blood of the patients and value the level of CA19-9, CA125 and CEA by using the chemiluminescent microparticle immunoassay（CMIA）. The cutoff level were established as 37(U/mL) for CA19-9, 35(U/mL) for CA125 and 10(ng/L) for CEA, the level above were considered as positive. The result of pathological diagnosis was considered as the golden standard. We analyzed the serum level of the three tumor markers and compared their diagnostic result with the golden standard. The data we gained were analyzed by SPSS11.0. Results: 1.Wilcoxon test showed the mean rank of the level of tumor markers CA19-9, CA125 and CEA in pancreatic cancer group was higher than that of benign p